<?xml version='1.0' encoding='utf-8'?>
<document id="24422646"><sentence text="Anidulafungin: advantage for the newcomer?"><entity charOffset="0-13" id="DDI-PubMed.24422646.s1.e0" text="Anidulafungin" /></sentence><sentence text="Anidulafungin is the most recently approved compound of the echinocandin antifungal class"><entity charOffset="0-13" id="DDI-PubMed.24422646.s2.e0" text="Anidulafungin" /><entity charOffset="60-72" id="DDI-PubMed.24422646.s2.e1" text="echinocandin" /><pair ddi="false" e1="DDI-PubMed.24422646.s2.e0" e2="DDI-PubMed.24422646.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24422646.s2.e0" e2="DDI-PubMed.24422646.s2.e1" /></sentence><sentence text=" Its mode of action is the noncompetitive inhibition of Î²-(1,3)-D-glucan synthesis" /><sentence text=" Potent fungicidal activity has been demonstrated against many Candida spp" /><sentence text=", including non-albicansCandida spp" /><sentence text=" and fluconazole-resistant strains, as well as fungistatic activity against Aspergillus spp"><entity charOffset="5-16" id="DDI-PubMed.24422646.s6.e0" text="fluconazole" /></sentence><sentence text=" Owing to low oral bioavailability, it can only be administered intravenously" /><sentence text=" Anidulafungin is not metabolized by the liver and renal clearance is negligible, thus rendering dosage adjustments in patients with impaired hepatic or renal function unnecessary"><entity charOffset="1-14" id="DDI-PubMed.24422646.s8.e0" text="Anidulafungin" /></sentence><sentence text=" Due to lack of interference with the cytochrome P450 pathway, it displays minimal drug-drug interaction" /><sentence text=" Anidulafungin has been approved by the US FDA for the treatment of esophageal and invasive candidiasis after clinical trials demonstrated its noninferiority to fluconazole"><entity charOffset="1-14" id="DDI-PubMed.24422646.s10.e0" text="Anidulafungin" /><entity charOffset="161-172" id="DDI-PubMed.24422646.s10.e1" text="fluconazole" /><pair ddi="false" e1="DDI-PubMed.24422646.s10.e0" e2="DDI-PubMed.24422646.s10.e0" /><pair ddi="false" e1="DDI-PubMed.24422646.s10.e0" e2="DDI-PubMed.24422646.s10.e1" /></sentence><sentence text=" In September 2007, anidulafungin gained EMEA approval for the treatment of invasive candidiasis in adult non-neutropenic patients" /><sentence text=" For those with invasive or noninvasive candidiasis with resistance or intolerance to fluconazole in particular, as well as those requiring antifungal medication, that anidulafungin does not interact with concomitant medication means it may be regarded as a safe and efficacious treatment option"><entity charOffset="86-97" id="DDI-PubMed.24422646.s12.e0" text="fluconazole" /><entity charOffset="168-181" id="DDI-PubMed.24422646.s12.e1" text="anidulafungin" /><pair ddi="false" e1="DDI-PubMed.24422646.s12.e0" e2="DDI-PubMed.24422646.s12.e0" /><pair ddi="false" e1="DDI-PubMed.24422646.s12.e0" e2="DDI-PubMed.24422646.s12.e1" /></sentence><sentence text=" Promising results from animal models and experience with the other echinocandins indicate several potential lines of investigation: invasive aspergillosis, prophylaxis and treatment of transplant patients, and empirical treatment in patients with febrile neutropenia"><entity charOffset="68-81" id="DDI-PubMed.24422646.s13.e0" text="echinocandins" /></sentence><sentence text=" Significant differences in clinical efficacy or safety favoring anidulafungin over the other echinocandins are yet to be discovered"><entity charOffset="65-78" id="DDI-PubMed.24422646.s14.e0" text="anidulafungin" /><entity charOffset="94-107" id="DDI-PubMed.24422646.s14.e1" text="echinocandins" /><pair ddi="false" e1="DDI-PubMed.24422646.s14.e0" e2="DDI-PubMed.24422646.s14.e0" /><pair ddi="false" e1="DDI-PubMed.24422646.s14.e0" e2="DDI-PubMed.24422646.s14.e1" /></sentence><sentence text=" " /></document>